Immune-mediated Tumor Cell Killing | InSphero

Immuno-oncology

Immune-mediated Tumor Cell Killing

Assess the effectiveness of immunotherapeutic strategies in vitro

3D InSight™ Tumor Microtissues can be tailored to assess antibody-based targeted tumor cell killing, such as immunotherapeutic strategies that seek to modulate the immune response by promoting recognition of tumor antigens by T-cells using monoclonal or bi-specific antibodies.

  • Reflect in vivo interaction between lymphocytes, tumor and stromal tissue components in vitro with 3D tumor models that more accurately mimic the complex tumor environment
  • Monitor tumor cell killing over time with phenotypic, biochemical, and immunohistochemical endpoints to assess immune infiltration, tumor cell killing, therapeutic specificity, and cytokine production
  • Incorporate your modified cell lines into advanced in vitro I-O studies by leveraging our robust production process that generates reproducible microtissues for more translatable results

Example Data

Immune-mediated tumor cell killing: A) IHC staining identifies the tumor-specific marker CEA (brown) in heterotypic LoVo (colon)/MRC-5 (fibroblast) microtissues treated with immunomodulatory antibodies causing immune-mediated cell death. Cell killing is tumor-specific as shown by removal of the outer cancer cell population. The stroma core region (fibroblasts) is not affected. B) Tumor cell elimination is quantifiable as measured by reduction in spheroid size (left) and by CEA staining followed by flow cytometric profiling of dissociated spheroids.

Request Additional Resources

Brochure: Oncology Services

Request

Poster: 3D InSight™ Oncology Drug Discovery Platform

Request

Find out how you can screen immunotherapeutics

using advanced 3D tumor models.

Get Started